Literature DB >> 3539328

Performance status assessment among oncology patients: a review.

S T Orr, J Aisner.   

Abstract

Performance status is a global assessment of a patient's ability for self-care and ambulation. It is an important and widely used prognostic variable for patients with cancer. Several different scales to assess performance status are in use, and scale scores are used for a variety of purposes, including patient selection and stratification for cancer clinical trials. New uses for life quality evaluations have also been proposed. Despite the widespread use of the scales, little information is available about the reliability and validity of these measures. Improved and extended application of these scales requires that several types of data about measurement properties of the scales be collected and analyzed. Various issues related to the measurement properties of the scales and their implications for oncology need to be understood to best develop their use.

Entities:  

Mesh:

Year:  1986        PMID: 3539328

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

1.  Psychometric testing of the Impact of Event Scale-Chinese Version (IES-C) in oral cancer patients in Taiwan.

Authors:  Shu-Ching Chen; Yeur-Hur Lai; Chun-Ta Liao; Chia-Chin Lin
Journal:  Support Care Cancer       Date:  2005-02-17       Impact factor: 3.603

2.  Assessment of solid cancer treatment feasibility in older patients: a prospective cohort study.

Authors:  Marie Laurent; Elena Paillaud; Christophe Tournigand; Philippe Caillet; Aurélie Le Thuaut; Jean-Léon Lagrange; Olivier Beauchet; Hélène Vincent; Muriel Carvahlo-Verlinde; Stéphane Culine; Sylvie Bastuji-Garin; Florence Canouï-Poitrine
Journal:  Oncologist       Date:  2014-02-25

3.  QOL and Survival Comparisons by Race in Oncology Clinical Trials.

Authors:  A D Tan; P J Novotny; J S Kaur; J C Buckner; R B Mowat; E Paskett; J A Sloan
Journal:  J Cancer Clin Oncol       Date:  2016-11-16

4.  Quality of life in low-income patients with metastatic prostate cancer: divergent and convergent validity of three instruments.

Authors:  L K Sharp; S J Knight; R Nadler; M Albers; E Moran; T Kuzel; R Sharifi; C Bennett
Journal:  Qual Life Res       Date:  1999-08       Impact factor: 4.147

Review 5.  The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.

Authors:  Lakshmi Nayak; Lisa M DeAngelis; Alba A Brandes; David M Peereboom; Evanthia Galanis; Nancy U Lin; Riccardo Soffietti; David R Macdonald; Marc Chamberlain; James Perry; Kurt Jaeckle; Minesh Mehta; Roger Stupp; Alona Muzikansky; Elena Pentsova; Timothy Cloughesy; Fabio M Iwamoto; Joerg-Christian Tonn; Michael A Vogelbaum; Patrick Y Wen; Martin J van den Bent; David A Reardon
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

6.  Quality of life for oncology patients during the terminal period. Validation of the HRCA-QL index.

Authors:  Joan Llobera; Magdalena Esteva; Enric Benito; Josefa Terrasa; Juli Rifà; Onofre Pons; Ascensión Maya
Journal:  Support Care Cancer       Date:  2003-03-22       Impact factor: 3.603

7.  Patient acceptance and differential perceptions of quality of life measures in a French oncology setting.

Authors:  M Mercier; S Schraub; D D Bransfield; J Fournier
Journal:  Qual Life Res       Date:  1992-02       Impact factor: 4.147

Review 8.  Pediatric low-grade gliomas: next biologically driven steps.

Authors:  David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

9.  The Karnofsky Performance Status Scale re-examined: a cross-validation with the EORTC-C30.

Authors:  J Schaafsma; D Osoba
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

Review 10.  The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach.

Authors:  David E Dawe; Peter Michael Ellis
Journal:  Front Oncol       Date:  2014-07-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.